
Richard Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11693432/publications.pdf Version: 2024-02-01



РІСНАРО КІМ

#	Article	IF	CITATIONS
1	First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2016, 34, 4142-4150.	1.6	187
2	ls there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncology, The, 2009, 10, 903-912.	10.7	98
3	FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma. Cancer Treatment Reviews, 2019, 78, 1-7.	7.7	57
4	Prognostic roles of human equilibrative transporter 1 (<i>hENT</i> â€ <i>1</i>) and ribonucleoside reductase subunit M1 (<i>RRM1</i>) in resected pancreatic cancer. Cancer, 2011, 117, 3126-3134.	4.1	51
5	Safety and Feasibility of Using Sorafenib in Recurrent Hepatocellular Carcinoma after Orthotopic Liver Transplantation. Oncology, 2010, 79, 62-66.	1.9	48
6	Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clinical Transplantation, 2013, 27, 555-561.	1.6	46
7	Quantitative endoscopy: Precise computerized measurement of metaplastic epithelial surface area in Barrett's esophagus. Gastroenterology, 1995, 108, 360-366.	1.3	44
8	Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opinion on Investigational Drugs, 2018, 27, 709-720.	4.1	42
9	Geographic differences in approach to advanced gastric cancer: Is there a standard approach?. Critical Reviews in Oncology/Hematology, 2013, 88, 416-426.	4.4	39
10	Carboplatin and Paclitaxel Treatment Is Effective in Advanced Anal Cancer. Oncology, 2014, 87, 125-132.	1.9	39
11	Adjuvant Treatment for Gastric Cancer: Chemotherapy Versus Radiation. Oncologist, 2013, 18, 1013-1021.	3.7	38
12	Prevention and treatment of FGFR inhibitor-associated toxicities. Critical Reviews in Oncology/Hematology, 2020, 155, 103091.	4.4	35
13	Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Annals of Surgical Oncology, 2021, 28, 1939-1949.	1.5	31
14	Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Therapeutic Advances in Medical Oncology, 2012, 4, 341-346.	3.2	30
15	Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma. Oncotarget, 2018, 9, 23366-23372.	1.8	29
16	Radiologic Complete Response with Sirolimus and Sorafenib in a Hepatocellular Carcinoma Patient who Relapsed After Orthotopic Liver Transplantation. Journal of Gastrointestinal Cancer, 2011, 42, 50-53.	1.3	28
17	Management of borderline resectable pancreatic cancer. World Journal of Gastrointestinal Oncology, 2015, 7, 241.	2.0	27
18	Extent of Barrett's metaplasia: a prospective study of the serial change in area of Barrett's measured by quantitative endoscopic imaging. Gastrointestinal Endoscopy, 1997, 45, 456-462.	1.0	20

RICHARD KIM

0

#	Article	IF	CITATIONS
19	A Single Institution Review of Adjuvant Therapy Outcomes for Resectable Pancreatic Adenocarcinoma: Outcome and Prognostic Indicators. Journal of Gastrointestinal Surgery, 2010, 14, 1159-1169.	1.7	20
20	Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 236-241.	1.3	15
21	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. British Journal of Clinical Pharmacology, 2019, 85, 2499-2511.	2.4	14
22	Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. OncoTargets and Therapy, 2021, Volume 14, 5145-5160.	2.0	14
23	Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1281-1292.	4.9	11
24	Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. Radiotherapy and Oncology, 2016, 118, 382-386.	0.6	10
25	Gastric Electrical Stimulation Is an Option for Patients with Refractory Cyclic Vomiting Syndrome. Journal of Neurogastroenterology and Motility, 2016, 22, 643-649.	2.4	8
26	BRAF testing in advanced colorectal cancer: is it ready for prime time?. Clinical Advances in Hematology and Oncology, 2010, 8, 437-44.	0.3	8
27	Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. Expert Opinion on Investigational Drugs, 2021, 30, 451-461.	4.1	6
28	In Reply. Oncologist, 2014, 19, 431-431.	3.7	4
29	Locally Advanced Gastroesophageal Junction Tumor: A Treatment Dilemma. Oncologist, 2015, 20, 134-142.	3.7	4
30	Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. Oncologist, 2022, 27, 621-e617.	3.7	2
31	To Give or Not to Give Anti–Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies to Patients With KRAS G13D Mutation in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 85-87.	2.3	1
32	Personalized Medicine in Advanced Cholangiocarcinoma. Oncology & Hematology Review, 2020, 16, 52.	0.2	1
33	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. , 2020, , 731-757.		1
34	Investigational drugs for treating anal cancer and future perspectives. Expert Opinion on Investigational Drugs, 2016, 25, 51-62.	4.1	0
35	ASO Author Reflections: Evolving Treatment Paradigms for High-Risk Intrahepatic Cholangiocarcinoma: What Does The Future Hold?. Annals of Surgical Oncology, 2021, 28, 854-855.	1.5	0

Staging and Prognostic Implications. , 2018, , 109-118.

#	Article	IF	CITATIONS
37	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. , 2019, , 1-28.		0